| Ident. | Authors (with country if any) | Title |
|---|
| 000B40 |
Philippe Remy [France, Royaume-Uni] ; Miroslava Doder [Royaume-Uni] ; Andrew Lees [Royaume-Uni] ; Nora Turjanski [Royaume-Uni] ; David Brooks [Royaume-Uni] | Depression in Parkinson's disease : loss of dopamine and noradrenaline innervation in the limbic system |
| 000B98 |
Hélène Legros [France] ; Marie-George Dingeval [France] ; Francois Janin [France] ; Jean Costentin [France] ; Jean-Jacques Bonnet [France] | Toxicity of a treatment associating dopamine and disulfiram for catecholaminergic neuroblastoma SH-SY5Y cells: Relationships with 3,4-dihydroxyphenylacetaldehyde formation |
| 000C25 |
William J. Burke [États-Unis] ; SHU WEN LI [États-Unis] ; Hyung D. Chung [États-Unis] ; David A. Ruggiero [États-Unis] ; Bruce S. Kristal [États-Unis] ; Eugene M. Johnson [États-Unis] ; Patricia Lampe [États-Unis] ; Vijaya B. Kumar [États-Unis] ; Mark Franko [États-Unis] ; Evelyn A. Williams [États-Unis] ; Daniel S. Zahm [États-Unis] | Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: Role in neurodegenerative diseases |
| 000C52 |
Makoto Naoi [Japon] ; Wakako Maruyama [Japon] ; Georgy M. Nagy [Hongrie] | Dopamine-derived salsolinol derivatives as endogenous monoamine oxidase inhibitors: Occurrence, metabolism and function in human brains |
| 000C60 |
N. Hamaue [Japon] ; M. Minami [Japon] ; M. Terado [Japon] ; M. Hirafuji [Japon] ; T. Endo [Japon] ; M. Machida [Japon] ; T. Hiroshige [Japon] ; A. Ogata [Japon] ; K. Tashiro [Japon] ; H. Saito [Japon] ; S. H. Parvez [France] | Comparative study of the effects of isatin, an endogenous MAO-inhibitor, and selegiline on bradykinesia and dopamine levels in a rat model of Parkinson's disease induced by the Japanese encephalitis virus |
| 000D42 |
Alan L. Whone [Royaume-Uni] ; Ray L. Watts [États-Unis] ; A. Jon Stoessl [Canada] ; Margaret Davis [États-Unis] ; Sven Reske [Allemagne] ; Claude Nahmias [Canada] ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Maria J. Ribeiro [France] ; Philippe Remy [France] ; Werner Poewe [Autriche] ; Robert A. Hauser [États-Unis] ; David J. Brooks [Royaume-Uni] | Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study |
| 000E89 |
Estelle Rousselet [France] ; Jacques Callebert [France] ; Karine Parain [France] ; Chantal Joubert [France] ; Stéphane Hunot [France] ; Andreas Hartmann [France] ; Claude Jacque [France] ; Fernando Perez-Diaz [France] ; Charles Cohen-Salmon [France] ; Jean-Marie Launay [France] ; Etienne C. Hirsch [France] | Role of TNF-α receptors in mice intoxicated with the parkinsonian toxin MPTP |
| 000F23 |
Yoko Hirata [Japon] | Manganese-induced apoptosis in PC12 cells |
| 000F44 |
Aïcha Douhou [France] ; Thomas Debeir [France] ; Mario Gustavo Murer [Argentine] ; Louis Do [France] ; Noëlle Dufour [France] ; Véronique Blanchard [France] ; Saliha Moussaoui [France] ; Georg Andrees Bohme [France] ; Yves Agid [France] ; Rita Raisman-Vozari [France] | Effect of chronic treatment with riluzole on the nigrostriatal dopaminergic system in weaver mutant mice |
| 001095 |
David Blum [Belgique, France] ; Sakina Torch [France] ; Marie-France Nissou [France] ; Jean-Marc Verna [France] | 6-hydroxydopamine-induced nuclear factor-kappab activation in PC12 cells |
| 001179 |
Saliha Moussaoui [France] ; Maria-Carmen Obinu [France] ; Nadine Daniel [France] ; Michel Reibaud [France] ; Véronique Blanchard [France] ; Assunta Imperato [France] | The antioxidant Ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson's disease |
| 001205 |
A.-M. Bonnet [France] | Involvement of non-dopaminergic pathways in Parkinson's disease : Pathophysiology and therapeutic implications |
| 001428 |
A. Boireau [France] ; M. Meunier [France] ; A. Imperato [France] | Ouabain-induced increase in dopamine release from mouse striatal slices is antagonized by riluzole |
| 001465 |
G. A. Qureshi [Suède] ; A. F. Ansari [Pakistan] ; A. Halawa [Suède] ; M. Minami [Japon] ; S. H. Parvez [France] | Cholecystokinins and their coexistence with catecholamines in cerebrospinal fluid of patients with some neurological disorders |
| 001474 |
| CONTRÔLE DE L'EXCITABILITÉ DES NEURONES DOPAMINERGIQUES DE LA SUBSTANCE NOIRE COMPACTE DE RAT PAR LES CATÉCHOLAMINES ET LES NEUROPEPTIDES |
| 001476 |
| Synthèse de Complexants Spécifiques de Catécholamines |
| 001477 |
| Développement de médicaments radiopharmaceutiques émetteurs de rayonnements gamma pour l'exploration du transporteur de la dopamine dans le système nerveux central |
| 001605 |
| Complexes de catecholamines avec les cations Mg(II), Co(II), Ni(II), Cu(II), Cd(II), Pb(II) et Fe(III). Stabilité en solution aqueuse |
| 001631 |
J. Mallet [France] | The TiPS/TINS Lecture Catecholamines : from gene regulation to neuropsychiatric disorders |
| 001672 |
M.-E. Llau [France] ; G. Durrieu [France] ; M.-A. Tran [France] ; J.-M. Senard [France] ; O. Rascol [France] ; J.-L. Montastruc [France] | A study of dopaminergic sensitivity in Parkinson's disease : Comparison in ''de novo'' and levodopa-treated patients |
| 001708 |
F. Thibaut [France] ; B. A. Faucheux [France] ; J. Marquez [France] ; J. Villares [France] ; J. F. Menard [France] ; Yves Agid [France] ; E. C. Hirsch [France] | Regional distribution of monoamine vesicular uptake sites in the mesencephalon of control subjects and patients with Parkinson's disease : a postmortem study using tritiated tetrabenazine |
| 001885 |
J. M. Senard [France] ; O. Rascol [France] ; G. Durrieu [France] ; M. A. Tran [France] ; M. Berlan [France] ; A. Rascol ; J. L. Montastruc | Effects of Yohimbine on plasma catecholamine levels in orthostatic hypotension related to Pakinson disease or multiple system atrophy |
| 001902 |
| Système nerveux autonome et maladie de Parkinson. Influence des médicaments antiparkinsoniens |
